Over the past several years, Glucagon-like peptide-1 receptor agonists (GLP-1s) have revolutionized the field of obesity treatment, providing results comparable to those achieved by bariatric surgery
You see, while Novo Nordisk and Eli Lilly had their great lucrative monopolies on these obesity drugs, it was basically on them to make enough of these drugs to meet demand
insulin resistance, poor sleep, stress, and muscle loss can all make weight loss harder
These are typically the final, large-scale studies needed before FDA review, and early data show promising weight loss results
Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans